How to Get to the Senior Levels of Scientific Management
#WESTpanel

Join us for a thought-provoking discussion on successful strategies for women in reaching top management in the sciences. A dynamic panel of women leaders will share their successes, and more importantly their lessons learned, as they have moved up the career ladder in scientific management. Come hear the wisdom of women leaders as they provide candid feedback and insightful advice on what enables women to reach the top.

 

Panelists: 

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer at Nimbus Therapeutics

Rosana Kapeller is the Chief Scientific Officer of Nimbus Therapeutics and has more than 20 years of leadership experience in the biotechnology industry. Prior to joining Nimbus, she was Co-Founder and Vice President of Research of Aileron Therapeutics, where she led the development of Aileron’s “Stapled Peptide” technology. Under her scientific leadership, Aileron secured $60 million in venture financing over its first four years. Prior to co-founding Aileron, Dr. Kapeller held positions of increasing responsibility at Millennium Pharmaceuticals, most recently serving as Director, Department of Molecular and Cellular Biology. She earned her M.D. from Rio de Janeiro State University in Brazil, and her Ph.D. from Tufts University Medical School. She conducted her post-doctoral research work at the Dana-Farber Cancer Institute where she was named a David Abraham Fellow in Pediatric Oncology. Dr. Kapeller has published extensively and filed more than 150 patent applications, of which 50 have been issued. In 2012, Dr. Kapeller was named one of the Top 20 Women to Watch by Mass High Tech. 

 

Dr. Rachel Meyers, Senior Vice President, Research at Alnylam Pharmaceuticals

Dr. Rachel Meyers is Vice President of Research and RNAi Lead Development (RLD) at Alnylam. In this capacity, she plays a key role in the advancement of Alnylam’s RNAi therapeutic programs, from early discovery through clinical development and her team is responsible for program leadership for most of Alnylam’s preclinical and clinical stage programs. In addition to leading the research organization, Dr. Meyers has worked closely with Alnylam’s business development group, playing an integral part in establishing important collaborations, and has functioned as a scientific lead in collaborations with Novartis, Takeda, Isis, Roche and Genzyme. She also led the scientific diligence resulting in Alnylam’s acquisition of the Sirna assets from Merck. Prior to taking on the leadership of the Research and RLD Groups, Dr. Meyers was one of Alnylam’s Research Directors, focusing her efforts on the development of RNAi therapeutics to target infectious diseases, and was the project lead for the company’s RSV program, where she was responsible for advancing ALN-RSV01 from inception, through pre-clinical development and into the clinic. Dr. Meyers was honored by Mass High Tech as one of 10 Women to Watch 2007 and by R & D Directions as one of its Top 20 Scientists 2007. Before joining Alnylam in April of 2003, Dr. Meyers was a Senior Scientist at Millennium Pharmaceuticals (1999-2003) where she was involved in the bioinformatics, molecular and cell biology of target discovery. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her Ph.D. from MIT in the field of in vitro transcription.  She serves as a Scientific Advisor to Editas Medicine.

 

Dr. Jo Viney, Vice President, Immunology Research at Biogen

Dr. Jo Viney is Vice President, Immunology Research at Biogen in Cambridge, MA. In this role, Jo is responsible for setting scientific research direction and strategy with a focus on target identification and validation for drug discovery and development for treating patients with autoimmune and inflammatory diseases. Jo received her PhD from St Bartholomew’s Hospital, University of London in 1991 and pursued postdoctoral fellowships first at the Imperial cancer Research Fund in London, UK, and at Genentech in the Bay Area, California. Following her training, Jo joined Immunex in 1995 and remained at the company, which was acquired by Amgen in 2002, until leaving to join Biogen Idec. Jo has advanced a portfolio of novel biologic and small molecule programs, seven of which have progressed to IND and into clinical development, for diseases such rheumatoid arthritis, asthma, atopic dermatitis, psoriasis, inflammatory bowel disease and lupus. Jo has maintained longstanding membership with the American Society of Immunologists (AAI), the British Society for Immunology (BSI) and the Society for Mucosal Immunology (SMI). She served as President of SMI from 2011-2013. Together with her SMI colleagues, she launched the journal Mucosal Immunology with Nature Publishing Group in 2007. Jo has been a member of the Scientific Advisory Board for Keystone Symposia since 2008, and she partners with KS on a number of programs for under-represented scientists. She is also member of the Scientific Advisory Board for the BioAster Technology Research Institute (IRT) in France, and for Vaxart Inc in the Bay Area. 

 

Moderator: 

 

Alexandra Glucksmann, Ph.D., Chief Operating Officer at Editas Medicine Inc.

Alexandra Glucksmann is Chief Operating Officer and founding employee at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics. Previously, Alexandra was Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products.  Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of science positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. She serves on the board of Women in the Enterprise of Science and Technology (WEST). Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.

 

 

Date and Time:  
November 19, 2015
6:00 - 8:30 PM

Agenda:

5:50-6:10pm: Registration, mingling, and light dinner
6:10-6:30pm: Facilitated networking
6:30-8:00pm: Panel Discussion
8:00-8:30pm: Optional networking

Location:  

Microsoft, One Cambridge Center, 4th Floor, Hawthorne Room, Cambridge, MA 02142

Map and Parking Information

We appreciate Microsoft donating the use of their event space.  Microsoft requires all attendees to check in on the first floor with a government issued photo id card.

Cost:   
Members: $35; Non-Members: $55, Workshop and Annual Membership: $120
A light dinner will be served.
 

To Register

 

 

 

If you are a student looking for financial assistance to attend this event, please visit www.stayinma.com.